Events & Presentations

Upcoming Events
Date Event Details Remind Me
Apr 3 - Apr 4, 2023
7th Complement UK Training Course and Symposium
Archived Events
Date Event Details
Feb 2, 2022 4:30 PM EST
Arrowhead Pharmaceuticals 2022 First Quarter Results
Dec 3, 2021
18th Global Cardiovascular Clinical Trialists Forum
James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
Dec 2, 2021 1:00 PM EST
4th Annual Evercore ISI HealthCONx Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 30, 2021
Piper Sandler 33rd Annual Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 22, 2021 4:30 PM EST
Arrowhead Pharmaceuticals 2021 Year End Results
Nov 16, 2021 11:50 AM EST
Jefferies London Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Nov 13 - Nov 17, 2021
American Heart Association (AHA) Scientific Sessions 2021

Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al.
Session: The Future of Lipidology: Novel and Emerging Interventions for Lipid Disorders

Nov 12 - Nov 15, 2021
The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

Title: ARO-AAT Treatment Reduces Intra-hepatic Z-AAT Leading to Improved Parameters of Liver Health and Fibrosis Regression
Authors: Pavel Strnad, et al.
Publication Number: LP11
Session: Late-breaking Abstract Posters

Title: ARO-HSD, An Investigational RNAi Therapeutic, Demonstrates Reduction in ALT and Hepatic HSD17B13 mRNA and Protein in Patients with NASH or Suspected NASH
Authors: Lung-Yi Mak, et al.
Publication Number: LP13
Session: Late-breaking Abstract Posters

Title: Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator (CAM) JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection (CHB): Results from the Phase 2B REEF-1 Study
Authors: Man Fung Yuen, et al.
Publication Number: LO10
Session: Late Breaking Session 2

Oct 26, 2021 3:00 PM EDT
ARO-C3 KOL Webinar
Oct 12, 2021 2:00 PM EDT
H.C. Wainwright 5th Annual NASH Investor Conference
James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine will participate in a fireside chat presentation